This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Melevodopa is a methyl ester of levodopa indicated in combination with carbidopa for the treatment of Parkinson's disease.
- Generic Name
- Melevodopa
- DrugBank Accession Number
- DB13313
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Melevodopa (DB13313)
- Weight
- Average: 211.217
Monoisotopic: 211.084457903 - Chemical Formula
- C10H13NO4
- Synonyms
- Melevodopa
- External IDs
- CHF-1301
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to manage Parkinson's disease (pd) Combination Product in combination with: Carbidopa (DB00190) •••••••••••• ••••• •••••••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmisulpride The therapeutic efficacy of Melevodopa can be decreased when used in combination with Amisulpride. Aripiprazole The therapeutic efficacy of Melevodopa can be decreased when used in combination with Aripiprazole. Aripiprazole lauroxil The therapeutic efficacy of Melevodopa can be decreased when used in combination with Aripiprazole lauroxil. Asenapine The therapeutic efficacy of Melevodopa can be decreased when used in combination with Asenapine. Brexpiprazole The therapeutic efficacy of Melevodopa can be decreased when used in combination with Brexpiprazole. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image SIRIO Melevodopa (250 MG) + Carbidopa (25 MG) Tablet Oral Chiesi Italia s.p.a 2014-07-08 2021-06-26 Italy 
SIRIO Melevodopa (125 MG) + Carbidopa (12.5 MG) Tablet Oral Chiesi Italia s.p.a 2015-04-01 Not applicable Italy SIRIO Melevodopa (100 MG) + Carbidopa (25 MG) Tablet Oral Chiesi Italia s.p.a 2014-07-08 2021-06-26 Italy SIRIO Melevodopa (100 MG) + Carbidopa (25 MG) Tablet Oral Chiesi Italia s.p.a 2015-04-01 Not applicable Italy SIRIO Melevodopa (125 MG) + Carbidopa (12.5 MG) Tablet Oral Chiesi Italia s.p.a 2015-04-01 Not applicable Italy
Categories
- ATC Codes
- N04BA04 — Melevodopa
- N04BA — Dopa and dopa derivatives
- N04B — DOPAMINERGIC AGENTS
- N04 — ANTI-PARKINSON DRUGS
- N — NERVOUS SYSTEM
- Drug Categories
- Amines
- Amino Acids
- Amino Acids, Aromatic
- Amino Acids, Cyclic
- Amino Acids, Peptides, and Proteins
- Anti-Dyskinesia Agents
- Anti-Parkinson Drugs
- Benzene Derivatives
- Catecholamines
- Catechols
- Central Nervous System Agents
- Dihydroxyphenylalanine
- Dopa and Dopa Derivatives
- Dopamine Agents
- Nervous System
- Phenols
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as tyrosine and derivatives. These are compounds containing tyrosine or a derivative thereof resulting from reaction of tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Tyrosine and derivatives
- Alternative Parents
- Phenylalanine and derivatives / Alpha amino acid esters / Amphetamines and derivatives / Catechols / Fatty acid esters / Aralkylamines / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Methyl esters / Monocarboxylic acids and derivatives show 5 more
- Substituents
- 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Alpha-amino acid ester / Amine / Amphetamine or derivatives / Aralkylamine / Aromatic homomonocyclic compound / Benzenoid / Carbonyl group / Carboxylic acid ester show 18 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- M30686U4X4
- CAS number
- 7101-51-1
- InChI Key
- XBBDACCLCFWBSI-ZETCQYMHSA-N
- InChI
- InChI=1S/C10H13NO4/c1-15-10(14)7(11)4-6-2-3-8(12)9(13)5-6/h2-3,5,7,12-13H,4,11H2,1H3/t7-/m0/s1
- IUPAC Name
- methyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
- SMILES
- COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1
References
- General References
- AIFA Product Information: Sirio (melevodopa/carbidopa) effervescent tablets [Link]
- External Links
- ChemSpider
- 21968
- ChEBI
- 134880
- ChEMBL
- CHEMBL1328898
- ZINC
- ZINC000019861870
- Wikipedia
- Melevodopa
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder, for solution Oral Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 2.15 mg/mL ALOGPS logP -0.2 ALOGPS logP 0.62 Chemaxon logS -2 ALOGPS pKa (Strongest Acidic) 9.29 Chemaxon pKa (Strongest Basic) 6.97 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 92.78 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 53.85 m3·mol-1 Chemaxon Polarizability 21.25 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0udi-2900000000-3e318b7f6ebb44f5a191 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0udr-0910000000-ffd58cfa5663569dbd70 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-0900000000-c64ebe9a8cadd6eed4b3 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0080-5900000000-ef906fb8c910cc3fda87 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-059i-7900000000-2ce3b0db1119c798c77a Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-001i-5900000000-339ead55b2ae5de364ee Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-05fr-8900000000-12aced97bcdb0e969f43 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 151.46475 predictedDeepCCS 1.0 (2019) [M+H]+ 153.8603 predictedDeepCCS 1.0 (2019) [M+Na]+ 159.87903 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:39 / Updated at June 02, 2021 20:04